Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention
Mustabshira Idrees, Hafsa Iftikhar, Fatima Sohail, Mustabshirah Jadoon, Muhammad Hanif Khan · 2026
Read Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention by Mustabshira Idrees, Hafsa Iftikhar, Fatima Sohail, Mustabshirah Jadoon, Muhammad Hanif Khan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13236187.txt.
Description
Mustabshira Idrees and four co-authors commented in 2026 on two trials of a twice-yearly HIV prevention shot. Global infections have fallen since 2010, yet cases rose among transgender women and gay and bisexual men, and daily prevention pills reach only a fraction of the global target. Long-acting options are the gap the trials addressed. The drug is lenacapavir, given by injection every six months.
PURPOSE-1 enrolled 5,338 young women and girls in Uganda and South Africa, comparing the shot with two daily pill regimens. PURPOSE-2 ran at 92 sites in seven countries with gender-diverse participants at high risk. The commentary frames the results as a breakthrough for prevention among the groups most affected.
Catalog record
| CREATOR | Mustabshira Idrees, Hafsa Iftikhar, Fatima Sohail, Mustabshirah Jadoon, Muhammad Hanif Khan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |